It is a proprietary nanoparticle formulation targeted at the transferrin receptor, containing non-chemically modified small interfering RNA (siRNA) against the M2 subunit of ribonucleotide reductase (RRM2), with potential anti-tumor activity. This evidence concerns the gene TFRC and neoplasm.